Articles: cations.
-
Retracted Publication
Measuring Postoperative Complications: On the Right Path but Far Away From the Destination.
The aim of the present study was to compare the proposed complication severity score (CSS) with comprehensive complication index (CCI) using a questionnaire-based survey of experienced gastrointestinal and hepato-pancreatico-biliary surgeons. ⋯ CCI was not accurate in calculating the severity of a combination of postoperative complications. The CSS more often matched the opinion of experienced senior surgeons but requires further modifications.
-
Neoadjuvant chemotherapy (NACT) is increasingly being offered to patients with breast cancer. No survival benefit has been demonstrated for NACT, but it may serve to reduce tumour size and improve prognosis through the attainment of a pathological complete response (pCR). The role and mode of MRI monitoring during NACT remain unclear. ⋯ NACT allows identification of patient subgroups within TNBC and Her2-positive cohorts with a good prognosis. MRI can be used to identify patients who are responding to treatment.
-
Review Meta Analysis
30-day Readmission After Pancreatic Resection: A Systematic Review of the Literature and Meta-analysis.
The aim of this study was to identify and compare common reasons and risk factors for 30-day readmission after pancreatic resection. ⋯ Readmission after pancreatic resection is common and can largely be attributed to infectious complications and inability to maintain adequate hydration and nutrition. Focus on outpatient resources and follow-up to address these issues will prove valuable in reducing readmissions.
-
Randomized Controlled Trial
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures. ⋯ The Moulton Foundation, the Berkeley Foundation, the Multiple Sclerosis Trials Collaboration, the Rosetrees Trust, a personal contribution from A W Pidgley CBE, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre and University College London.